



## Clinical trial results:

**Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyrimidine and bevacizumab vs. bevacizumab alone vs. no maintenance treatment and reinduction in case of progression for first-line treatment of patients with metastatic colorectal cancer**

### Summary

EudraCT number	2008-007974-39
Trial protocol	DE
Global end of trial date	14 August 2015

### Results information

Result version number	v1 (current)
This version publication date	21 November 2021
First version publication date	21 November 2021

### Trial information

#### Trial identification

Sponsor protocol code	AIO-KRK-0207
-----------------------	--------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00973609
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	AIO-Studien-gGmbH
Sponsor organisation address	Kuno-Fischer-Str. 8, Berlin, Germany, 14057
Public contact	info@aio-studien-ggmbh.de, AIO-Studien-gGmbH, info@aio-studien-ggmbh.de
Scientific contact	info@aio-studien-ggmbh.de, AIO-Studien-gGmbH, info@aio-studien-ggmbh.de

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 December 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	14 August 2015
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Investigating the efficacy of maintenance and reinduction treatment or no treatment and watchful waiting in subjects with inoperable or irresectable and non-progressive metastatic colorectal cancer after first line induction treatment for 24 weeks with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy. The maintenance treatment with capecitabine or 5-FU/folinic acid and bevacizumab will be compared with a maintenance treatment with bevacizumab alone or no maintenance treatment. Reinduction treatment will be done in case of progression.

Primary end-point:

Time to failure of maintenance and reinduction treatment strategy measured from randomization.

Protection of trial subjects:

This study was planned, analyzed and conducted according to the study protocol and in accordance with the International Conference on Harmonization (ICH) 'Guideline for Good Clinical Practice E6(R1)', CPMP/ICH/135/95, based on the principles of the Declaration of Helsinki (1964) and its October 1996 amendment (Somerset West, South Africa). The study was duly conducted in compliance with the German Arzneimittelgesetz (AMG; German Drug Law), and the corresponding Directive 2001/20/EC. Subjects were fully informed regarding all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the subject.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	17 September 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 825
Worldwide total number of subjects	825
EEA total number of subjects	825

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	385
From 65 to 84 years	440
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

837 subjects were recruited between Sept 17, 2009 and Feb 21, 2013, from 106 German institutions (55 hospitals and 51 private practices).

### Pre-assignment

Screening details:

Of 852 screened patients, 837 received induction treatment. 12 of these patients were not eligible for analysis due to major protocol violations.

### Period 1

Period 1 title	Induction treatment
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Induction overall
-----------	-------------------

Arm description:

For induction treatment, the investigator had to choose between a capecitabine based or a 5-fluorouracil / FA based chemotherapy regimen for each subject. Allowed regimens were CAPOX, XELOX, FOLFOX6, FOLFOX4, modified FOLFOX7, modified FOLFOX4, and simplified FOLFOX4.

A change of the regimen was allowed if necessary.

Arm type	Standard-of-care induction treatment
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

7.5 mg/kg every 3 weeks, or 5 mg/kg every 2 weeks

Investigational medicinal product name	Fluoropyrimidine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Concentrate for solution for infusion
Routes of administration	Intravenous use, Oral use

Dosage and administration details:

Capecitabine oral at 1000 mg/m<sup>2</sup> twice daily or 5-FU infusion as stipulated by the regimen chosen by the investigator.

Investigational medicinal product name	Oxaliplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Dosage was 70 mg/m<sup>2</sup>, 85 mg/m<sup>2</sup>, 100 mg/m<sup>2</sup>, or 130 mg/m<sup>2</sup>, depending on the treatment regimen chosen by the investigator.

Number of subjects in period 1	Induction overall
Started	825
Completed	825

## Period 2

Period 2 title	Maintenance treatment
Is this the baseline period?	Yes <sup>[1]</sup>
Allocation method	Randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Arm 1 (SoC)

Arm description:

Maintenance treatment according to standard-of-care (SoC) with fluoropyrimidine plus bevacizumab until progression or unacceptable toxicity, i.e. any of the permitted induction treatments minus oxaliplatin.

Arm type	Active comparator
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

7.5 mg/kg every 3 weeks, or 5 mg/kg every 2 weeks

Investigational medicinal product name	Fluoropyrimidine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion, Tablet
Routes of administration	Intravenous use, Oral use

Dosage and administration details:

Dosage and administration as given during induction treatment

<b>Arm title</b>	Arm 2 (beva maintenance)
------------------	--------------------------

Arm description:

Maintenance treatment with bevacizumab until progression or unacceptable toxicity

Arm type	Experimental
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

7.5 mg/kg IV infusion, if tolerated over 30 minutes day 1, 22; start of next cycle on day 43

<b>Arm title</b>	Arm 3 (no maintenance treatment)
------------------	----------------------------------

Arm description:	
No maintenance treatment until progression	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

Notes:

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: Period 1 was non-randomized induction treatment according to standard of care. This period is of little scientific interest compared to the experimental treatment phase and therefore was not chosen as baseline period for the purpose of this reporting.

Number of subjects in period 2 <sup>[2]</sup> [3]	Arm 1 (SoC)	Arm 2 (beva maintenance)	Arm 3 (no maintenace treatment)
Started	158	156	158
Completed	158	156	158

Notes:

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Period 2 is the experimental phase of the study, and only patients who proceeded to period 2 contributed to the primary endpoint. It was chosen as baseline period for this reason.

[3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: As per study protocol, only a subset of patients who received induction treatment proceeded to the phase of randomized, experimental maintenance treatment. Main reasons for not proceeding to maintenance treatment were disease progression during induction treatment, unacceptable toxicity and other adverse events preventing further treatment.

### Period 3

Period 3 title	Re-induction treatment
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
Arm title	Arm 1 (SoC)

Arm description:

Re-induction treatment according to SoC after disease progression during standard-of-care maintenance

Arm type	Re-induction of standard-of-care
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

7.5 mg/kg every 3 weeks, or 5 mg/kg every 2 weeks, depending on the treatment regimen chosen by the investigator.

Investigational medicinal product name	Fluoropyrimidine
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Concentrate for solution for infusion, Tablet
Routes of administration	Intravenous use, Oral use
Dosage and administration details:	
Capecitabine oral at 1000 mg/m <sup>2</sup> twice daily or 5-FU infusion as stipulated by the regimen chosen by the investigator.	
Investigational medicinal product name	Oxaliplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Dosage was 70 mg/m <sup>2</sup> , 85 mg/m <sup>2</sup> , 100 mg/m <sup>2</sup> , or 130 mg/m <sup>2</sup> , depending on the treatment regimen chosen by the investigator.	
<b>Arm title</b>	Arm 2
Arm description:	
Re-induction treatment according to SoC after disease progression during bevacizumab maintenance treatment	
Arm type	Re-induction of standard-of-care
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use
Dosage and administration details:	
7.5 mg/kg every 3 weeks, or 5 mg/kg every 2 weeks, depending on the treatment regimen chosen by the investigator.	
Investigational medicinal product name	Fluoropyrimidine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Concentrate for solution for infusion
Routes of administration	Intravenous use, Oral use
Dosage and administration details:	
Capecitabine oral at 1000 mg/m <sup>2</sup> twice daily or 5-FU infusion as stipulated by the regimen chosen by the investigator.	
Investigational medicinal product name	Oxaliplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Dosage was 70 mg/m <sup>2</sup> , 85 mg/m <sup>2</sup> , 100 mg/m <sup>2</sup> , or 130 mg/m <sup>2</sup> , depending on the treatment regimen chosen by the investigator.	
<b>Arm title</b>	Arm 3
Arm description:	
Re-induction treatment according to SoC after disease progression without maintenance treatment	
Arm type	Re-induction of standard-of-care
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use
Dosage and administration details:	
7.5 mg/kg every 3 weeks, or 5 mg/kg every 2 weeks, depending on the treatment regimen chosen by	

the investigator.

Investigational medicinal product name	Fluoropyrimidine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion, Tablet
Routes of administration	Intravenous use, Oral use

Dosage and administration details:

Capecitabine oral at 1000 mg/m<sup>2</sup> twice daily or 5-FU infusion as stipulated by the regimen chosen by the investigator.

Investigational medicinal product name	Oxaliplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Dosage was 70 mg/m<sup>2</sup>, 85 mg/m<sup>2</sup>, 100 mg/m<sup>2</sup>, or 130 mg/m<sup>2</sup>, depending on the treatment regimen chosen by the investigator.

<b>Number of subjects in period 3<sup>[4]</sup></b>	Arm 1 (SoC)	Arm 2	Arm 3
Started	33	67	75
Completed	33	67	75

Notes:

[4] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: As per study protocol, only a subset of patients proceeded to re-induction. Reasons for treatment discontinuation during maintenance treatment were death, unacceptable toxicity, patient's wish, and decisions to make use of alternative treatment options.



## Baseline characteristics

### Reporting groups

Reporting group title	Arm 1 (SoC)
Reporting group description: Maintenance treatment according to standard-of-care (SoC) with fluoropyrimidine plus bevacizumab until progression or unacceptable toxicity, i.e. any of the permitted induction treatments minus oxaliplatin.	
Reporting group title	Arm 2 (beva maintenance)
Reporting group description: Maintenance treatment with bevacizumab until progression or unacceptable toxicity	
Reporting group title	Arm 3 (no maintenance treatment)
Reporting group description: No maintenance treatment until progression	

Reporting group values	Arm 1 (SoC)	Arm 2 (beva maintenance)	Arm 3 (no maintenance treatment)
Number of subjects	158	156	158
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
median	64	65	66
full range (min-max)	25 to 82	32 to 82	32 to 82
Gender categorical Units: Subjects			
Female	52	50	59
Male	106	106	99
ECOG performance score Units: Subjects			
ECOG 0-1	151	150	151
ECOG 2	7	6	7

Reporting group values	Total		
Number of subjects	472		
Age categorical Units: Subjects			
In utero	0		

Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age continuous Units: years median full range (min-max)	-		
Gender categorical Units: Subjects			
Female	161		
Male	311		
ECOG performance score Units: Subjects			
ECOG 0-1	452		
ECOG 2	20		

## End points

### End points reporting groups

Reporting group title	Induction overall
Reporting group description: For induction treatment, the investigator had to choose between a capecitabine based or a 5-fluorouracil / FA based chemotherapy regimen for each subject. Allowed regimens were CAPOX, XELOX, FOLFOX6, FOLFOX4, modified FOLFOX7, modified FOLFOX4, and simplified FOLFOX4.  A change of the regimen was allowed if necessary.	
Reporting group title	Arm 1 (SoC)
Reporting group description: Maintenance treatment according to standard-of-care (SoC) with fluoropyrimidine plus bevacizumab until progression or unacceptable toxicity, i.e. any of the permitted induction treatments minus oxaliplatin.	
Reporting group title	Arm 2 (beva maintenance)
Reporting group description: Maintenance treatment with bevacizumab until progression or unacceptable toxicity	
Reporting group title	Arm 3 (no maintenance treatment)
Reporting group description: No maintenance treatment until progression	
Reporting group title	Arm 1 (SoC)
Reporting group description: Re-induction treatment according to SoC after disease progression during standard-of-care maintenance	
Reporting group title	Arm 2
Reporting group description: Re-induction treatment according to SoC after disease progression during bevacizumab maintenance treatment	
Reporting group title	Arm 3
Reporting group description: Re-induction treatment according to SoC after disease progression without maintenance treatment	

### Primary: Time to failure of strategy (TFS)

End point title	Time to failure of strategy (TFS)
End point description: Time to failure of strategy from randomization (TFS from randomization): time from randomization to the first of the following events: death; patient requires the addition of a new therapeutic agent (i.e. an agent not included in the original strategy; end point measured at the first of either the time of disease progression or the time of initiation of a new agent); patient experiences disease progression while being treated with all agents that are components of the initial treatment strategy (except for agents which cannot be used because of persistent toxicity or contraindications); or patient experiences disease progression during a partial or complete treatment holiday from initial treatment strategy and receives no further therapy within 1 month. Subjects who did not have an event as stated above while on study were censored at the last evaluable radiographic assessment date.	
End point type	Primary
End point timeframe: TFS was measured in months between randomization and initiation of second-line treatment. Median follow-up from randomization was 17.0 months.	

End point values	Arm 1 (SoC)	Arm 2 (beva maintenance)	Arm 3 (no maintenance treatment)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	147	153	154	
Units: Months				
number (confidence interval 95%)	6.9 (6.1 to 8.5)	6.1 (5.3 to 7.4)	6.4 (4.8 to 7.6)	

## Statistical analyses

<b>Statistical analysis title</b>	SoC vs. beva maintenance
Comparison groups	Arm 1 (SoC) v Arm 2 (beva maintenance)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.85
upper limit	1.37

<b>Statistical analysis title</b>	SoC vs. no maintenance
Comparison groups	Arm 3 (no maintenance treatment) v Arm 1 (SoC)
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.6

## Secondary: Progression-free survival 1

End point title	Progression-free survival 1
End point description:	Progression-free survival time of induction treatment (PFS1): time from randomization to date of first observed progression or death (whichever comes first) over the entire trial. Subjects who have not progressed while on study and have not died while on study were censored at the last evaluable radiographic assessment date.
End point type	Secondary

End point timeframe:

Time from randomization to date of first observed progression or death. Median follow-up from randomization was 17.0 months.

End point values	Arm 1 (SoC)	Arm 2 (beva maintenance)	Arm 3 (no maintenace treatment)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	147	153	154	
Units: Months				
median (confidence interval 95%)	6.3 (5.8 to 7.6)	4.6 (4.0 to 5.3)	3.5 (2.9 to 4.1)	

### Statistical analyses

<b>Statistical analysis title</b>	Comparison of Arm 2 to standard Arm 1
Comparison groups	Arm 1 (SoC) v Arm 2 (beva maintenance)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Hazard ratio (HR)
Point estimate	1.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.06
upper limit	1.7

<b>Statistical analysis title</b>	Copy of Comparison of Arm 3 to standard Arm 1
Comparison groups	Arm 1 (SoC) v Arm 3 (no maintenace treatment)
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Hazard ratio (HR)
Point estimate	2.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.64
upper limit	2.67

### Secondary: Overall survival

End point title	Overall survival
-----------------	------------------

End point description:

Overall survival time (OS): time from randomization to the date of death. Subjects who were known to be alive or for whom a date of death was unknown, were censored on the later date of the last study assessment or last known telephone contact.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from randomization to the date of death. Median follow-up from randomization was 17.0 months.

End point values	Arm 1 (SoC)	Arm 2 (beva maintenance)	Arm 3 (no maintenace treatment)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	157	156	158	
Units: Months				
median (confidence interval 95%)	20.2 (18.4 to 24.3)	21.9 (18.7 to 26.4)	23.1 (19.6 to 25.7)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Progression-free survival 2

End point title	Progression-free survival 2
-----------------	-----------------------------

End point description:

PFS2: Time from enrolment to first progression event for all randomized patients. All other definitions as for PFS1.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from enrolment to first progression event for all randomized patients. Median follow-up from randomization was 17.0 months.

End point values	Arm 1 (SoC)	Arm 2 (beva maintenance)	Arm 3 (no maintenace treatment)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	147	153	154	
Units: Months				
median (confidence interval 95%)	11.7 (10.8 to 13.2)	10.0 (9.4 to 10.6)	9 (8.4 to 9.6)	

## Statistical analyses

No statistical analyses for this end point

## Adverse events

---

### Adverse events information

---

Timeframe for reporting adverse events:

Adverse events were collected from informed consent until 28 days after the last administration of treatment.

Adverse events for individual treatment phases are from the first cycle of the respective step until the the corresponding safety update visit.

Adverse event reporting additional description:

The results for 'total number of deaths - all causes' refer to the overall death event number in all patients reaching the respective treatment phase, irrespective of the time point of death.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	NCI CTCAE
-----------------	-----------

Dictionary version	3
--------------------	---

### Reporting groups

Reporting group title	Arm 1 Maintenance
-----------------------	-------------------

Reporting group description:

Fluoropyrimidine plus bevacizumab until progression or unacceptable toxicity

The results for 'total number of deaths - all causes' refer to the overall death event number in all patients reaching the respective treatment phase, irrespective of the time point of death.

Reporting group title	Arm 3 Maintenance
-----------------------	-------------------

Reporting group description:

No treatment until progression

The results for 'total number of deaths - all causes' refer to the overall death event number in all patients reaching the respective treatment phase, irrespective of the time point of death.

Reporting group title	Arm 2 Maintenance
-----------------------	-------------------

Reporting group description:

Bevacizumab until progression or unacceptable toxicity

The results for 'total number of deaths - all causes' refer to the overall death event number in all patients reaching the respective treatment phase, irrespective of the time point of death.

Reporting group title	Induction period
-----------------------	------------------

Reporting group description:

The database structure does not allow to analyze overall mortality in individual treatment step periods. Thus, these results for 'total number of deaths - all causes' refer to the overall death event number in all patients reaching the respective treatment phase, irrespective of the time point of death.

Reporting group title	Arm 1 Re-Induction
-----------------------	--------------------

Reporting group description: -

Reporting group title	Arm 2 Re-Induction
-----------------------	--------------------

Reporting group description:

The results for 'total number of deaths - all causes' refer to the overall death event number in all patients reaching the respective treatment phase, irrespective of the time point of death.

Reporting group title	Arm 3 Re-Induction
-----------------------	--------------------

Reporting group description: -

<b>Serious adverse events</b>	Arm 1 Maintenance	Arm 3 Maintenance	Arm 2 Maintenance
Total subjects affected by serious adverse events			
subjects affected / exposed	31 / 158 (19.62%)	20 / 158 (12.66%)	37 / 156 (23.72%)
number of deaths (all causes)	115	104	120
number of deaths resulting from adverse events	8	5	6
Vascular disorders			
Hemorrhage/Bleeding - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis (including superficial thrombosis)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebolympathic cording			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic synd			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute vascular leak syndrome			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Flushing			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			



subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	2 / 156 (1.28%)
occurrences causally related to treatment / all	0 / 3	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial ischemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis/thrombus/embolism			
subjects affected / exposed	2 / 158 (1.27%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	8 / 9	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Extremity-lower (gait/walking)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - General - Tumor pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Other			
subjects affected / exposed	2 / 158 (1.27%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight loss			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death not associated with CTCAE term - Disease progression NOS			
subjects affected / exposed	2 / 158 (1.27%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Death not associated with CTCAE term - Multi-organ failure			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constitutional Symptoms - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	6 / 156 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 4
Death not associated with CTCAE term			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Death not associated with CTCAE term - Death NOS			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Death not associated with CTCAE term - Sudden death			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 1
Edema: limb			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fatigue (asthenia, lethargy, malaise)			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	2 / 156 (1.28%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fever (in the absence of neutropenia)			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syndromes - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis/embolism (vascular access-related)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulceration			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Allergic reaction/hypersensitivity (including drug fever)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Allergy/Immunology - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Atelectasis			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm, wheezing			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, pulmonary/upper respiratory - Nose			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion (non-malignant)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Dyspnea (shortness of breath)			
subjects affected / exposed	2 / 158 (1.27%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC - Pulmonary/Upper Respiratory - Lung (pneumonia)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis/pulmonary infiltrates			

subjects affected / exposed	3 / 158 (1.90%)	1 / 158 (0.63%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	1 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pulmonary/Upper Respiratory - Other			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusion			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mood alteration - Anxiety			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Metabolic/Laboratory - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fracture			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage/bleeding associated with surgery, intra-operative or postoperative			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-operative injury - Gastrointestinal - Stoma (GI)			

subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vessel injury-vein			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound complication, non-infectious			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-operative Injury - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Left ventricular diastolic dysfunction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ventricular arrhythmia - Ventricular fibrillation			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiac Arrhythmia - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac General - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac ischemia/infarction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Cardiac troponin T (cTnT)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Cardiovascular - Pericardium			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia - Ventricular arrhythmia NOS			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Encephalopathy			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy: cranial - CN V Motor-jaw muscles; Sensory-facial			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Neuropathy: cranial - CN VII Motor-face; Sensory-taste			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Speech impairment (e.g., dysphasia or aphasia)			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tremor			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy: cranial - CN II Vision			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CNS cerebrovascular ischemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurology - Other			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Neuropathy: sensory			



subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Neurology - Head/headache			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope (fainting)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphatics - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood/Bone Marrow - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulation - Other			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	4 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia (fever of unknown origin, ANC <1.0 x 10e9/L)			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemoglobin			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - General - Blood			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytes (total WBC)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophils/granulocytes (ANC/AGC)			
subjects affected / exposed	1 / 158 (0.63%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Platelets			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Retinal detachment			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula, GI - Anus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flatulence			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GI			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GI - Colon			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GI - Esophagus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GI - Stoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucositis/stomatitis (functional/symptomatic) - Stomach			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrosis, GI - Gallbladder			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction, GI - Ileum			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Gastrointestinal - Abdomen NOS			
subjects affected / exposed	1 / 158 (0.63%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Gastrointestinal - Anus			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Gastrointestinal - Stomach			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prolapse of stoma, GI			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stricture/stenosis (including anastomotic), GI - Duodenum			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stricture/stenosis (including anastomotic), GI - Ileum			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites (non-malignant)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction, GI			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Gastrointestinal - Peritoneum			

subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhea			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia (difficulty swallowing)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis (inflammation of the small bowel)			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula, GI			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis (including bile reflux gastritis)			
subjects affected / exposed	2 / 158 (1.27%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	1 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal - Other			
subjects affected / exposed	1 / 158 (0.63%)	1 / 158 (0.63%)	6 / 156 (3.85%)
occurrences causally related to treatment / all	0 / 1	0 / 1	2 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GI - Rectum			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation)			
subjects affected / exposed	1 / 158 (0.63%)	2 / 158 (1.27%)	3 / 156 (1.92%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Gastrointestinal - Peritoneal cavity			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malabsorption			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucositis/stomatitis (clinical exam)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucositis/stomatitis (clinical exam) - Anus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucositis/stomatitis (clinical exam) - Oral cavity			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucositis/stomatitis (functional/symptomatic) - Oral cavity			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucositis/stomatitis (functional/symptomatic) - Pharynx			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrosis, GI - Ileum			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction, GI - Gallbladder			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perforation, GI - Colon			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perforation, GI - Small bowel NOS			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stricture/stenosis (including anastomotic), GI - Colon			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcer, GI - Duodenum			

subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcer, GI - Stomach			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatobiliary/Pancreas - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Hepatobiliary/Pancreas - Gallbladder			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Hepatobiliary/Pancreas - Liver			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver dysfunction/failure (clinical)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bilirubin (hyperbilirubinemia)			
subjects affected / exposed	0 / 158 (0.00%)	2 / 158 (1.27%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			



subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GGT (gamma-Glutamyl transpeptidase)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash/desquamation			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatology/Skin - Other			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Creatinine			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula, GU			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction, GU - Ureter			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal/Genitourinary - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Stricture/stenosis (including anastomotic), GU - Prostate			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stricture/stenosis (including anastomotic), GU - Ureter			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention (including neurogenic bladder)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adrenal insufficiency			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerular filtration rate			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GU - Bladder			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Renal/Genitourinary - Bladder			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	2 / 156 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	5 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Endocrine - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Pain - Musculoskeletal - Bone			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Musculoskeletal - Extremity-limb			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Musculoskeletal - Muscle			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal/Soft Tissue - Other			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Musculoskeletal - Back			
subjects affected / exposed	3 / 158 (1.90%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Gastrointestinal - Abdomen NOS			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Gastrointestinal - Dental-tooth			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - General - Catheter-related			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Lung (pneumonia)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection - Other			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Dermatology/Skin - Lip/perioral			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Dermatology/Skin - Peristomal			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Gastrointestinal - Abdomen NOS			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - General - Catheter-related			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - General - Foreign body (e.g.,graft, implant			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	1 / 156 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Pulmonary/Upper Respiratory - Bronchus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Renal/Genitourinary - Urinary tract NOS			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC -			

Gastrointestinal - Colon				
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Infection with unknown ANC - Gastrointestinal - Rectum				
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Infection with unknown ANC - General - Blood				
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Infection with unknown ANC - General - Catheter-related				
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Infection with unknown ANC - Pulmonary/Upper Respiratory - Upper airway NOS				
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - General - Blood				
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0	
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Urinary tract NOS				
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Cystitis				

subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC - Renal/Genitourinary - Urinary tract NOS			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Acidosis (metabolic or respiratory)			
subjects affected / exposed	0 / 158 (0.00%)	1 / 158 (0.63%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol intolerance syndrome (antabuse-like syndrome)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glucose, serum-high (hyperglycemia)			
subjects affected / exposed	1 / 158 (0.63%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Potassium, serum-high (hyperkalemia)			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Potassium, serum-low (hypokalemia)			

subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Anorexia</b>			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Dehydration</b>			
subjects affected / exposed	0 / 158 (0.00%)	0 / 158 (0.00%)	0 / 156 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Induction period	Arm 1 Re-Induction	Arm 2 Re-Induction
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	295 / 825 (35.76%)	6 / 33 (18.18%)	18 / 67 (26.87%)
number of deaths (all causes)	596	30	51
number of deaths resulting from adverse events		2	3
<b>Vascular disorders</b>			
<b>Hemorrhage/Bleeding - Other</b>			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Phlebitis (including superficial thrombosis)</b>			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Phlebolympathic cording</b>			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic synd</b>			



subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute vascular leak syndrome			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flushing			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	7 / 825 (0.85%)	1 / 33 (3.03%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	5 / 12	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 4	0 / 2	0 / 0
Hypotension			
subjects affected / exposed	3 / 825 (0.36%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	3 / 4	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial ischemia			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	7 / 7	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis/thrombus/embolism			
subjects affected / exposed	27 / 825 (3.27%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	29 / 45	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
General disorders and administration site conditions			
Extremity-lower (gait/walking)			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			

subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - General - Tumor pain			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Other			
subjects affected / exposed	4 / 825 (0.48%)	1 / 33 (3.03%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight loss			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death not associated with CTCAE term - Disease progression NOS			
subjects affected / exposed	5 / 825 (0.61%)	1 / 33 (3.03%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 5	0 / 0	0 / 1
Death not associated with CTCAE term - Multi-organ failure			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Constitutional Symptoms - Other			
subjects affected / exposed	24 / 825 (2.91%)	0 / 33 (0.00%)	2 / 67 (2.99%)
occurrences causally related to treatment / all	17 / 37	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 3
Death not associated with CTCAE term			
subjects affected / exposed	1 / 825 (0.12%)	1 / 33 (3.03%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	1 / 1	0 / 0
Death not associated with CTCAE			

term - Death NOS				
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Death not associated with CTCAE term - Sudden death				
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0	
Edema: limb				
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Fatigue (asthenia, lethargy, malaise)				
subjects affected / exposed	5 / 825 (0.61%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	7 / 7	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Fever (in the absence of neutropenia)				
subjects affected / exposed	11 / 825 (1.33%)	0 / 33 (0.00%)	1 / 67 (1.49%)	
occurrences causally related to treatment / all	5 / 15	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Syndromes - Other				
subjects affected / exposed	3 / 825 (0.36%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Thrombosis/embolism (vascular access-related)				
subjects affected / exposed	6 / 825 (0.73%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	4 / 10	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Ulceration				
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	

Immune system disorders			
Allergic reaction/hypersensitivity (including drug fever)			
subjects affected / exposed	4 / 825 (0.48%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	4 / 4	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Allergy/Immunology - Other			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Atelectasis			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm, wheezing			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, pulmonary/upper respiratory - Nose			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion (non-malignant)			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			

subjects affected / exposed	0 / 825 (0.00%)	1 / 33 (3.03%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Dyspnea (shortness of breath)			
subjects affected / exposed	9 / 825 (1.09%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	4 / 16	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 0
Infection with unknown ANC - Pulmonary/Upper Respiratory - Lung (pneumonia)			
subjects affected / exposed	3 / 825 (0.36%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis/pulmonary infiltrates			
subjects affected / exposed	10 / 825 (1.21%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	3 / 12	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 3	0 / 0	0 / 0
Pulmonary/Upper Respiratory - Other			
subjects affected / exposed	8 / 825 (0.97%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	6 / 11	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 4	0 / 0	0 / 0
Psychiatric disorders			
Confusion			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mood alteration - Anxiety			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Metabolic/Laboratory - Other			

subjects affected / exposed	3 / 825 (0.36%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	2 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fracture			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage/bleeding associated with surgery, intra-operative or postoperative			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-operative injury - Gastrointestinal - Stoma (GI)			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vessel injury-vein			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound complication, non-infectious			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-operative Injury - Other			
subjects affected / exposed	3 / 825 (0.36%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Left ventricular diastolic dysfunction			

subjects affected / exposed	0 / 825 (0.00%)	1 / 33 (3.03%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia - Ventricular fibrillation			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac Arrhythmia - Other			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac General - Other			
subjects affected / exposed	7 / 825 (0.85%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	4 / 7	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac ischemia/infarction			
subjects affected / exposed	6 / 825 (0.73%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	6 / 7	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac troponin T (cTnT)			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pain - Cardiovascular - Pericardium			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia - Ventricular arrhythmia NOS			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nervous system disorders			
Encephalopathy			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy: cranial - CN V Motor-jaw muscles; Sensory-facial			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy: cranial - CN VII Motor-face; Sensory-taste			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Speech impairment (e.g., dysphasia or aphasia)			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tremor			



subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy: cranial - CN II Vision			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
CNS cerebrovascular ischemia			
subjects affected / exposed	4 / 825 (0.48%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	4 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	2 / 2	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	4 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurology - Other			
subjects affected / exposed	4 / 825 (0.48%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy: sensory			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Neurology - Head/headache			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope (fainting)			
subjects affected / exposed	4 / 825 (0.48%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	4 / 4	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphatics - Other			

subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood/Bone Marrow - Other			
subjects affected / exposed	5 / 825 (0.61%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	4 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Coagulation - Other			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	5 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia (fever of unknown origin, ANC <1.0 x 10e9/L)			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemoglobin			
subjects affected / exposed	4 / 825 (0.48%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 9	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - General - Blood			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytes (total WBC)			
subjects affected / exposed	5 / 825 (0.61%)	1 / 33 (3.03%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	5 / 6	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Neutrophils/granulocytes (ANC/AGC)			
subjects affected / exposed	11 / 825 (1.33%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	16 / 17	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Platelets			

subjects affected / exposed	0 / 825 (0.00%)	2 / 33 (6.06%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Retinal detachment			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	2 / 825 (0.24%)	1 / 33 (3.03%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula, GI - Anus			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flatulence			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GI			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GI - Colon			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GI - Esophagus			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GI - Stoma			

subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucositis/stomatitis (functional/symptomatic) - Stomach			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrosis, GI - Gallbladder			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction, GI - Ileum			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Gastrointestinal - Abdomen NOS			
subjects affected / exposed	7 / 825 (0.85%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 13	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Gastrointestinal - Anus			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Gastrointestinal - Stomach			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prolapse of stoma, GI			

subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 6	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stricture/stenosis (including anastomotic), GI - Duodenum			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stricture/stenosis (including anastomotic), GI - Ileum			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites (non-malignant)			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 0
Obstruction, GI			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pain - Gastrointestinal - Peritoneum			
subjects affected / exposed	0 / 825 (0.00%)	1 / 33 (3.03%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Colitis			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhea			
subjects affected / exposed	35 / 825 (4.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	39 / 53	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia (difficulty swallowing)			

subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis (inflammation of the small bowel)			
subjects affected / exposed	3 / 825 (0.36%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula, GI			
subjects affected / exposed	3 / 825 (0.36%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis (including bile reflux gastritis)			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal - Other			
subjects affected / exposed	17 / 825 (2.06%)	1 / 33 (3.03%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	6 / 22	0 / 1	2 / 2
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 0
Hemorrhage, GI - Rectum			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation)			
subjects affected / exposed	17 / 825 (2.06%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	3 / 22	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 5	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Gastrointestinal - Peritoneal cavity			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Malabsorption				
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Mucositis/stomatitis (clinical exam)				
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Mucositis/stomatitis (clinical exam) - Anus				
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Mucositis/stomatitis (clinical exam) - Oral cavity				
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Mucositis/stomatitis (functional/symptomatic) - Oral cavity				
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Mucositis/stomatitis (functional/symptomatic) - Pharynx				
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Nausea				
subjects affected / exposed	7 / 825 (0.85%)	0 / 33 (0.00%)	1 / 67 (1.49%)	
occurrences causally related to treatment / all	4 / 10	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Necrosis, GI - Ileum				

subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction, GI - Gallbladder			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perforation, GI - Colon			
subjects affected / exposed	3 / 825 (0.36%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perforation, GI - Small bowel NOS			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stricture/stenosis (including anastomotic), GI - Colon			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcer, GI - Duodenum			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcer, GI - Stomach			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	14 / 825 (1.70%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	15 / 17	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatobiliary/Pancreas - Other			



subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Hepatobiliary/Pancreas - Gallbladder			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Hepatobiliary/Pancreas - Liver			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver dysfunction/failure (clinical)			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Bilirubin (hyperbilirubinemia)			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	2 / 67 (2.99%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GGT (gamma-Glutamyl transpeptidase)			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	5 / 5	0 / 0	8 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash/desquamation			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatology/Skin - Other			

subjects affected / exposed	2 / 825 (0.24%)	1 / 33 (3.03%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 2	4 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Creatinine			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula, GU			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction, GU - Ureter			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal/Genitourinary - Other			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stricture/stenosis (including anastomotic), GU - Prostate			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stricture/stenosis (including anastomotic), GU - Ureter			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention (including neurogenic bladder)			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Adrenal insufficiency			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerular filtration rate			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemorrhage, GU - Bladder			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Renal/Genitourinary - Bladder			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	7 / 825 (0.85%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	4 / 7	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Endocrine - Other			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Pain - Musculoskeletal - Bone			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Musculoskeletal - Extremity-limb			

subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain - Musculoskeletal - Muscle			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal/Soft Tissue - Other			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Pain - Musculoskeletal - Back			
subjects affected / exposed	3 / 825 (0.36%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	3 / 6	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Gastrointestinal - Abdomen NOS			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Gastrointestinal - Dental-tooth			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - General - Catheter-related			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Lung (pneumonia)			

subjects affected / exposed	3 / 825 (0.36%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Infection - Other			
subjects affected / exposed	13 / 825 (1.58%)	1 / 33 (3.03%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	8 / 18	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	2 / 67 (2.99%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Dermatology/Skin - Lip/perioral			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Dermatology/Skin - Peristomal			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Gastrointestinal - Abdomen NOS			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - General - Catheter-related			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - General - Foreign body (e.g.,graft, implant			

subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Pulmonary/Upper Respiratory - Bronchus			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with normal ANC or Grade 1 or 2 neutrophils - Renal/Genitourinary - Urinary tract NOS			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC - Gastrointestinal - Colon			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC - Gastrointestinal - Rectum			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC - General - Blood			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC - General - Catheter-related			

subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC - Pulmonary/Upper Respiratory - Upper airway NOS			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - General - Blood			
subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Urinary tract NOS			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with unknown ANC - Renal/Genitourinary - Urinary tract NOS			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Acidosis (metabolic or respiratory)			

subjects affected / exposed	0 / 825 (0.00%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol intolerance syndrome (antabuse-like syndrome)			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glucose, serum-high (hyperglycemia)			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Potassium, serum-high (hyperkalemia)			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Potassium, serum-low (hypokalemia)			
subjects affected / exposed	1 / 825 (0.12%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anorexia			
subjects affected / exposed	2 / 825 (0.24%)	0 / 33 (0.00%)	0 / 67 (0.00%)
occurrences causally related to treatment / all	3 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	8 / 825 (0.97%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences causally related to treatment / all	6 / 11	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Arm 3 Re-Induction		
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 74 (21.62%)		
number of deaths (all causes)	50		
number of deaths resulting from adverse events	2		



Vascular disorders				
Hemorrhage/Bleeding - Other				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Phlebitis (including superficial thrombosis)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Phlebolympathic cording				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic synd				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute vascular leak syndrome				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Flushing				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertension				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypotension				

subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral arterial ischemia			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombosis/thrombus/embolism			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Extremity-lower (gait/walking)			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain - General - Tumor pain			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Weight loss			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death not associated with CTCAE term - Disease progression NOS			

subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Death not associated with CTCAE term - Multi-organ failure				
subjects affected / exposed	1 / 74 (1.35%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Constitutional Symptoms - Other				
subjects affected / exposed	2 / 74 (2.70%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 1			
Death not associated with CTCAE term				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Death not associated with CTCAE term - Death NOS				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Death not associated with CTCAE term - Sudden death				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Edema: limb				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fatigue (asthenia, lethargy, malaise)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Fever (in the absence of neutropenia)				
subjects affected / exposed	1 / 74 (1.35%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Syndromes - Other				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thrombosis/embolism (vascular access-related)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ulceration				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Immune system disorders				
Allergic reaction/hypersensitivity (including drug fever)				
subjects affected / exposed	2 / 74 (2.70%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Allergy/Immunology - Other				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
Atelectasis				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchospasm, wheezing				

subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hemorrhage, pulmonary/upper respiratory - Nose				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleural effusion (non-malignant)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumothorax				
subjects affected / exposed	1 / 74 (1.35%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Aspiration				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dyspnea (shortness of breath)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with unknown ANC - Pulmonary/Upper Respiratory - Lung (pneumonia)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonitis/pulmonary infiltrates				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary/Upper Respiratory -				

Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Confusion			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mood alteration - Anxiety			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Metabolic/Laboratory - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Fracture			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hemorrhage/bleeding associated with surgery, intra-operative or postoperative			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intra-operative injury - Gastrointestinal - Stoma (GI)			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vessel injury-vein			

subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound complication, non-infectious			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intra-operative Injury - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Left ventricular diastolic dysfunction			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular arrhythmia			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular arrhythmia - Ventricular fibrillation			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac Arrhythmia - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Cardiac General - Other				
subjects affected / exposed	1 / 74 (1.35%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Cardiac ischemia/infarction				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac troponin T (cTnT)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pain - Cardiovascular - Pericardium				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ventricular arrhythmia - Ventricular arrhythmia NOS				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nervous system disorders				
Encephalopathy				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neuropathy: cranial - CN V Motor-jaw muscles; Sensory-facial				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neuropathy: cranial - CN VII Motor-face; Sensory-taste				



subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Seizure				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Speech impairment (e.g., dysphasia or aphasia)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tremor				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neuropathy: cranial - CN II Vision				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
CNS cerebrovascular ischemia				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dizziness				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neurology - Other				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neuropathy: sensory				

subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain - Neurology - Head/headache			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope (fainting)			
subjects affected / exposed	1 / 74 (1.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Blood and lymphatic system disorders			
Lymphatics - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood/Bone Marrow - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coagulation - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia (fever of unknown origin, ANC <1.0 x 10e9/L)			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hemoglobin			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection with normal ANC or Grade 1 or 2 neutrophils - General - Blood			

subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukocytes (total WBC)			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutrophils/granulocytes (ANC/AGC)			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Platelets			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Retinal detachment			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fistula, GI - Anus			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Flatulence			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hemorrhage, GI			

subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hemorrhage, GI - Colon				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hemorrhage, GI - Esophagus				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hemorrhage, GI - Stoma				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mucositis/stomatitis (functional/symptomatic) - Stomach				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Necrosis, GI - Gallbladder				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Obstruction, GI - Ileum				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pain - Gastrointestinal - Abdomen NOS				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pain - Gastrointestinal - Anus				

subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pain - Gastrointestinal - Stomach				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatitis				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Prolapse of stoma, GI				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Stricture/stenosis (including anastomotic), GI - Duodenum				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Stricture/stenosis (including anastomotic), GI - Ileum				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ascites (non-malignant)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Obstruction, GI				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pain - Gastrointestinal - Peritoneum				

subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colitis				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diarrhea				
subjects affected / exposed	1 / 74 (1.35%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Dysphagia (difficulty swallowing)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Enteritis (inflammation of the small bowel)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fistula, GI				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastritis (including bile reflux gastritis)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal - Other				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hemorrhage, GI - Rectum				

subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation)				
subjects affected / exposed	1 / 74 (1.35%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infection with normal ANC or Grade 1 or 2 neutrophils - Gastrointestinal - Peritoneal cavity				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malabsorption				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mucositis/stomatitis (clinical exam)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mucositis/stomatitis (clinical exam) - Anus				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mucositis/stomatitis (clinical exam) - Oral cavity				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mucositis/stomatitis (functional/symptomatic) - Oral cavity				

subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mucositis/stomatitis (functional/symptomatic) - Pharynx				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nausea				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Necrosis, GI - Ileum				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Obstruction, GI - Gallbladder				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Perforation, GI - Colon				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Perforation, GI - Small bowel NOS				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Stricture/stenosis (including anastomotic), GI - Colon				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ulcer, GI - Duodenum				



subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ulcer, GI - Stomach			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Hepatobiliary/Pancreas - Other			
subjects affected / exposed	1 / 74 (1.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pain - Hepatobiliary/Pancreas - Gallbladder			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain - Hepatobiliary/Pancreas - Liver			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Liver dysfunction/failure (clinical)			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bilirubin (hyperbilirubinemia)			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			

subjects affected / exposed	1 / 74 (1.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
GGT (gamma-Glutamyl transpeptidase)			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Rash/desquamation			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dermatology/Skin - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Creatinine			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fistula, GU			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Obstruction, GU - Ureter			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal/Genitourinary - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Stricture/stenosis (including anastomotic), GU - Prostate				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Stricture/stenosis (including anastomotic), GU - Ureter				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary retention (including neurogenic bladder)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Adrenal insufficiency				
subjects affected / exposed	1 / 74 (1.35%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 3			
Glomerular filtration rate				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hemorrhage, GU - Bladder				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Renal/Genitourinary - Bladder				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal failure				

subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Endocrine - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Pain - Musculoskeletal - Bone			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain - Musculoskeletal - Extremity-limb			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain - Musculoskeletal - Muscle			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal/Soft Tissue - Other			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain - Musculoskeletal - Back			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Gastrointestinal - Abdomen NOS			

subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Gastrointestinal - Dental-tooth				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - General - Catheter-related				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Lung (pneumonia)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection - Other				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with normal ANC or Grade 1 or 2 neutrophils				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with normal ANC or Grade 1 or 2 neutrophils - Dermatology/Skin - Lip/perioral				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with normal ANC or Grade 1 or 2 neutrophils - Dermatology/Skin - Peristomal				

subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with normal ANC or Grade 1 or 2 neutrophils - Gastrointestinal - Abdomen NOS				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with normal ANC or Grade 1 or 2 neutrophils - General - Catheter-related				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with normal ANC or Grade 1 or 2 neutrophils - General - Foreign body (e.g.,graft, implant				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with normal ANC or Grade 1 or 2 neutrophils - Pulmonary/Upper Respiratory - Bronchus				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with normal ANC or Grade 1 or 2 neutrophils - Renal/Genitourinary - Urinary tract NOS				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with unknown ANC				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with unknown ANC -				

Gastrointestinal - Colon				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with unknown ANC - Gastrointestinal - Rectum				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with unknown ANC - General - Blood				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with unknown ANC - General - Catheter-related				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with unknown ANC - Pulmonary/Upper Respiratory - Upper airway NOS				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - General - Blood				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) - Urinary tract NOS				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystitis				

subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with unknown ANC - Renal/Genitourinary - Urinary tract NOS				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metabolism and nutrition disorders				
Acidosis (metabolic or respiratory)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Alcohol intolerance syndrome (antabuse-like syndrome)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Glucose, serum-high (hyperglycemia)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Potassium, serum-high (hyperkalemia)				
subjects affected / exposed	0 / 74 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Potassium, serum-low (hypokalemia)				



subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Anorexia</b>			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Dehydration</b>			
subjects affected / exposed	0 / 74 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Arm 1 Maintenance	Arm 3 Maintenance	Arm 2 Maintenance
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	149 / 158 (94.30%)	138 / 158 (87.34%)	147 / 156 (94.23%)
<b>Vascular disorders</b>			
Hypertension			
subjects affected / exposed	20 / 158 (12.66%)	16 / 158 (10.13%)	26 / 156 (16.67%)
occurrences (all)	108	51	122
<b>Nervous system disorders</b>			
Neurology - Other			
subjects affected / exposed	12 / 158 (7.59%)	5 / 158 (3.16%)	9 / 156 (5.77%)
occurrences (all)	46	14	34
Neuropathy: sensory			
subjects affected / exposed	112 / 158 (70.89%)	112 / 158 (70.89%)	113 / 156 (72.44%)
occurrences (all)	577	387	560
Pain - Neurology - Head/headache			
subjects affected / exposed	5 / 158 (3.16%)	0 / 158 (0.00%)	3 / 156 (1.92%)
occurrences (all)	16	0	14
<b>Blood and lymphatic system disorders</b>			
Bilirubin (hyperbilirubinemia)			
subjects affected / exposed	4 / 158 (2.53%)	0 / 158 (0.00%)	2 / 156 (1.28%)
occurrences (all)	17	0	5
Blood/Bone Marrow - Other			

subjects affected / exposed occurrences (all)	6 / 158 (3.80%) 19	2 / 158 (1.27%) 6	1 / 156 (0.64%) 1
Hemoglobin subjects affected / exposed occurrences (all)	8 / 158 (5.06%) 29	11 / 158 (6.96%) 21	14 / 156 (8.97%) 41
Leukocytes (total WBC) subjects affected / exposed occurrences (all)	12 / 158 (7.59%) 28	5 / 158 (3.16%) 7	13 / 156 (8.33%) 23
Neutrophils/granulocytes (ANC/AGC) subjects affected / exposed occurrences (all)	6 / 158 (3.80%) 8	2 / 158 (1.27%) 2	8 / 156 (5.13%) 15
Platelets subjects affected / exposed occurrences (all)	16 / 158 (10.13%) 63	7 / 158 (4.43%) 17	23 / 156 (14.74%) 70
General disorders and administration site conditions			
Constitutional Symptoms - Other subjects affected / exposed occurrences (all)	9 / 158 (5.70%) 14	7 / 158 (4.43%) 15	6 / 156 (3.85%) 11
Fatigue (asthenia, lethargy, malaise) subjects affected / exposed occurrences (all)	43 / 158 (27.22%) 157	31 / 158 (19.62%) 84	27 / 156 (17.31%) 90
Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10 <sup>9</sup> /L) subjects affected / exposed occurrences (all)	4 / 158 (2.53%) 4	0 / 158 (0.00%) 0	4 / 156 (2.56%) 4
Pain - Other subjects affected / exposed occurrences (all)	7 / 158 (4.43%) 32	5 / 158 (3.16%) 9	10 / 156 (6.41%) 22
Gastrointestinal disorders			
Constipation subjects affected / exposed occurrences (all)	12 / 158 (7.59%) 33	5 / 158 (3.16%) 9	13 / 156 (8.33%) 30
Diarrhea subjects affected / exposed occurrences (all)	26 / 158 (16.46%) 82	12 / 158 (7.59%) 24	20 / 156 (12.82%) 55
Gastrointestinal - Other			

subjects affected / exposed	6 / 158 (3.80%)	4 / 158 (2.53%)	15 / 156 (9.62%)
occurrences (all)	27	16	48
Mucositis/stomatitis (clinical exam)			
subjects affected / exposed	5 / 158 (3.16%)	3 / 158 (1.90%)	6 / 156 (3.85%)
occurrences (all)	16	3	16
Mucositis/stomatitis (clinical exam) - Oral cavity			
subjects affected / exposed	10 / 158 (6.33%)	3 / 158 (1.90%)	7 / 156 (4.49%)
occurrences (all)	38	3	28
Nausea			
subjects affected / exposed	20 / 158 (12.66%)	13 / 158 (8.23%)	15 / 156 (9.62%)
occurrences (all)	60	21	43
Pain - Gastrointestinal - Abdomen NOS			
subjects affected / exposed	7 / 158 (4.43%)	12 / 158 (7.59%)	4 / 156 (2.56%)
occurrences (all)	13	25	6
Taste alteration (dysgeusia)			
subjects affected / exposed	10 / 158 (6.33%)	5 / 158 (3.16%)	4 / 156 (2.56%)
occurrences (all)	31	9	8
Vomiting			
subjects affected / exposed	7 / 158 (4.43%)	3 / 158 (1.90%)	4 / 156 (2.56%)
occurrences (all)	13	3	4
Hepatobiliary disorders			
AST, SGOT(serum glutamic oxaloacetic transaminase)			
subjects affected / exposed	1 / 158 (0.63%)	3 / 158 (1.90%)	10 / 156 (6.41%)
occurrences (all)	2	5	30
GGT (gamma-Glutamyl transpeptidase)			
subjects affected / exposed	1 / 158 (0.63%)	1 / 158 (0.63%)	4 / 156 (2.56%)
occurrences (all)	7	3	14
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	6 / 158 (3.80%)	1 / 158 (0.63%)	3 / 156 (1.92%)
occurrences (all)	13	2	14
Dyspnea (shortness of breath)			
subjects affected / exposed	8 / 158 (5.06%)	6 / 158 (3.80%)	6 / 156 (3.85%)
occurrences (all)	21	17	20

Hemorrhage, pulmonary/upper respiratory - Nose subjects affected / exposed occurrences (all)	8 / 158 (5.06%) 25	7 / 158 (4.43%) 14	8 / 156 (5.13%) 24
Skin and subcutaneous tissue disorders Dermatology/Skin - Other subjects affected / exposed occurrences (all)	13 / 158 (8.23%) 31	8 / 158 (5.06%) 30	5 / 156 (3.21%) 8
Hair loss/alopecia (scalp or body) subjects affected / exposed occurrences (all)	13 / 158 (8.23%) 45	12 / 158 (7.59%) 25	16 / 156 (10.26%) 47
Rash: hand-foot skin reaction subjects affected / exposed occurrences (all)	18 / 158 (11.39%) 74	9 / 158 (5.70%) 18	9 / 156 (5.77%) 41
Musculoskeletal and connective tissue disorders Musculoskeletal/Soft Tissue - Other subjects affected / exposed occurrences (all)	4 / 158 (2.53%) 8	3 / 158 (1.90%) 16	5 / 156 (3.21%) 12
Pain - Musculoskeletal - Back subjects affected / exposed occurrences (all)	6 / 158 (3.80%) 25	3 / 158 (1.90%) 5	4 / 156 (2.56%) 14
Pain - Musculoskeletal - Bone subjects affected / exposed occurrences (all)	1 / 158 (0.63%) 5	3 / 158 (1.90%) 6	7 / 156 (4.49%) 13
Pain - Musculoskeletal - Extremity- limb subjects affected / exposed occurrences (all)	2 / 158 (1.27%) 7	2 / 158 (1.27%) 5	7 / 156 (4.49%) 26
Infections and infestations Infection - Other subjects affected / exposed occurrences (all)	6 / 158 (3.80%) 22	2 / 158 (1.27%) 2	2 / 156 (1.28%) 2
Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all)	7 / 158 (4.43%) 21	7 / 158 (4.43%) 11	7 / 156 (4.49%) 15
Metabolic/Laboratory - Other			

subjects affected / exposed	3 / 158 (1.90%)	3 / 158 (1.90%)	7 / 156 (4.49%)
occurrences (all)	10	9	20
Weight loss			
subjects affected / exposed	8 / 158 (5.06%)	6 / 158 (3.80%)	7 / 156 (4.49%)
occurrences (all)	29	12	19

<b>Non-serious adverse events</b>	Induction period	Arm 1 Re-Induction	Arm 2 Re-Induction
Total subjects affected by non-serious adverse events			
subjects affected / exposed	825 / 825 (100.00%)	25 / 33 (75.76%)	61 / 67 (91.04%)
Vascular disorders			
Hypertension			
subjects affected / exposed	137 / 825 (16.61%)	3 / 33 (9.09%)	10 / 67 (14.93%)
occurrences (all)	403	10	40
Nervous system disorders			
Neurology - Other			
subjects affected / exposed	46 / 825 (5.58%)	4 / 33 (12.12%)	2 / 67 (2.99%)
occurrences (all)	126	15	6
Neuropathy: sensory			
subjects affected / exposed	524 / 825 (63.52%)	13 / 33 (39.39%)	47 / 67 (70.15%)
occurrences (all)	2107	64	210
Pain - Neurology - Head/headache			
subjects affected / exposed	40 / 825 (4.85%)	2 / 33 (6.06%)	0 / 67 (0.00%)
occurrences (all)	67	2	0
Blood and lymphatic system disorders			
Bilirubin (hyperbilirubinemia)			
subjects affected / exposed	12 / 825 (1.45%)	1 / 33 (3.03%)	5 / 67 (7.46%)
occurrences (all)	27	1	10
Blood/Bone Marrow - Other			
subjects affected / exposed	21 / 825 (2.55%)	2 / 33 (6.06%)	0 / 67 (0.00%)
occurrences (all)	53	4	0
Hemoglobin			
subjects affected / exposed	83 / 825 (10.06%)	1 / 33 (3.03%)	10 / 67 (14.93%)
occurrences (all)	229	3	40
Leukocytes (total WBC)			
subjects affected / exposed	133 / 825 (16.12%)	1 / 33 (3.03%)	8 / 67 (11.94%)
occurrences (all)	323	1	21
Neutrophils/granulocytes (ANC/AGC)			

subjects affected / exposed	116 / 825 (14.06%)	3 / 33 (9.09%)	3 / 67 (4.48%)
occurrences (all)	262	5	5
Platelets			
subjects affected / exposed	122 / 825 (14.79%)	4 / 33 (12.12%)	14 / 67 (20.90%)
occurrences (all)	317	14	53
General disorders and administration site conditions			
Constitutional Symptoms - Other			
subjects affected / exposed	92 / 825 (11.15%)	1 / 33 (3.03%)	5 / 67 (7.46%)
occurrences (all)	217	7	16
Fatigue (asthenia, lethargy, malaise)			
subjects affected / exposed	288 / 825 (34.91%)	7 / 33 (21.21%)	15 / 67 (22.39%)
occurrences (all)	965	19	54
Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L)			
subjects affected / exposed	49 / 825 (5.94%)	1 / 33 (3.03%)	4 / 67 (5.97%)
occurrences (all)	67	2	5
Pain - Other			
subjects affected / exposed	51 / 825 (6.18%)	1 / 33 (3.03%)	3 / 67 (4.48%)
occurrences (all)	103	7	8
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	101 / 825 (12.24%)	3 / 33 (9.09%)	1 / 67 (1.49%)
occurrences (all)	221	9	1
Diarrhea			
subjects affected / exposed	259 / 825 (31.39%)	5 / 33 (15.15%)	7 / 67 (10.45%)
occurrences (all)	605	18	15
Gastrointestinal - Other			
subjects affected / exposed	92 / 825 (11.15%)	3 / 33 (9.09%)	3 / 67 (4.48%)
occurrences (all)	204	17	14
Mucositis/stomatitis (clinical exam)			
subjects affected / exposed	40 / 825 (4.85%)	1 / 33 (3.03%)	4 / 67 (5.97%)
occurrences (all)	125	2	13
Mucositis/stomatitis (clinical exam) - Oral cavity			
subjects affected / exposed	94 / 825 (11.39%)	0 / 33 (0.00%)	6 / 67 (8.96%)
occurrences (all)	209	0	7

Nausea			
subjects affected / exposed	268 / 825 (32.48%)	7 / 33 (21.21%)	5 / 67 (7.46%)
occurrences (all)	718	27	16
Pain - Gastrointestinal - Abdomen NOS			
subjects affected / exposed	53 / 825 (6.42%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences (all)	95	0	2
Taste alteration (dysgeusia)			
subjects affected / exposed	44 / 825 (5.33%)	0 / 33 (0.00%)	1 / 67 (1.49%)
occurrences (all)	138	0	1
Vomiting			
subjects affected / exposed	130 / 825 (15.76%)	1 / 33 (3.03%)	5 / 67 (7.46%)
occurrences (all)	219	1	8
Hepatobiliary disorders			
AST, SGOT(serum glutamic oxaloacetic transaminase)			
subjects affected / exposed	17 / 825 (2.06%)	0 / 33 (0.00%)	5 / 67 (7.46%)
occurrences (all)	41	0	15
GGT (gamma-Glutamyl transpeptidase)			
subjects affected / exposed	2 / 825 (0.24%)	1 / 33 (3.03%)	4 / 67 (5.97%)
occurrences (all)	7	1	16
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	41 / 825 (4.97%)	1 / 33 (3.03%)	4 / 67 (5.97%)
occurrences (all)	61	1	12
Dyspnea (shortness of breath)			
subjects affected / exposed	59 / 825 (7.15%)	4 / 33 (12.12%)	2 / 67 (2.99%)
occurrences (all)	145	6	14
Hemorrhage, pulmonary/upper respiratory - Nose			
subjects affected / exposed	72 / 825 (8.73%)	1 / 33 (3.03%)	3 / 67 (4.48%)
occurrences (all)	176	3	9
Skin and subcutaneous tissue disorders			
Dermatology/Skin - Other			
subjects affected / exposed	61 / 825 (7.39%)	3 / 33 (9.09%)	3 / 67 (4.48%)
occurrences (all)	140	9	13
Hair loss/alopecia (scalp or body)			

subjects affected / exposed occurrences (all)	86 / 825 (10.42%) 299	0 / 33 (0.00%) 0	3 / 67 (4.48%) 11
Rash: hand-foot skin reaction subjects affected / exposed occurrences (all)	57 / 825 (6.91%) 159	5 / 33 (15.15%) 30	4 / 67 (5.97%) 17
Musculoskeletal and connective tissue disorders			
Musculoskeletal/Soft Tissue - Other subjects affected / exposed occurrences (all)	24 / 825 (2.91%) 37	0 / 33 (0.00%) 0	4 / 67 (5.97%) 10
Pain - Musculoskeletal - Back subjects affected / exposed occurrences (all)	26 / 825 (3.15%) 61	3 / 33 (9.09%) 9	3 / 67 (4.48%) 19
Pain - Musculoskeletal - Bone subjects affected / exposed occurrences (all)	25 / 825 (3.03%) 52	2 / 33 (6.06%) 7	2 / 67 (2.99%) 3
Pain - Musculoskeletal - Extremity- limb subjects affected / exposed occurrences (all)	23 / 825 (2.79%) 44	1 / 33 (3.03%) 1	5 / 67 (7.46%) 14
Infections and infestations			
Infection - Other subjects affected / exposed occurrences (all)	53 / 825 (6.42%) 90	1 / 33 (3.03%) 4	0 / 67 (0.00%) 0
Metabolism and nutrition disorders			
Anorexia subjects affected / exposed occurrences (all)	79 / 825 (9.58%) 182	0 / 33 (0.00%) 0	4 / 67 (5.97%) 8
Metabolic/Laboratory - Other subjects affected / exposed occurrences (all)	21 / 825 (2.55%) 82	0 / 33 (0.00%) 0	4 / 67 (5.97%) 16
Weight loss subjects affected / exposed occurrences (all)	70 / 825 (8.48%) 190	1 / 33 (3.03%) 3	3 / 67 (4.48%) 15

<b>Non-serious adverse events</b>	Arm 3 Re-Induction		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	69 / 74 (93.24%)		



Vascular disorders Hypertension subjects affected / exposed occurrences (all)	10 / 74 (13.51%) 47		
Nervous system disorders Neurology - Other subjects affected / exposed occurrences (all)  Neuropathy: sensory subjects affected / exposed occurrences (all)  Pain - Neurology - Head/headache subjects affected / exposed occurrences (all)	3 / 74 (4.05%) 11  57 / 74 (77.03%) 284  1 / 74 (1.35%) 3		
Blood and lymphatic system disorders Bilirubin (hyperbilirubinemia) subjects affected / exposed occurrences (all)  Blood/Bone Marrow - Other subjects affected / exposed occurrences (all)  Hemoglobin subjects affected / exposed occurrences (all)  Leukocytes (total WBC) subjects affected / exposed occurrences (all)  Neutrophils/granulocytes (ANC/AGC) subjects affected / exposed occurrences (all)  Platelets subjects affected / exposed occurrences (all)	0 / 74 (0.00%) 0  1 / 74 (1.35%) 2  6 / 74 (8.11%) 22  7 / 74 (9.46%) 18  3 / 74 (4.05%) 5  6 / 74 (8.11%) 8		
General disorders and administration site conditions Constitutional Symptoms - Other			

subjects affected / exposed	6 / 74 (8.11%)		
occurrences (all)	15		
Fatigue (asthenia, lethargy, malaise)			
subjects affected / exposed	21 / 74 (28.38%)		
occurrences (all)	83		
Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L)			
subjects affected / exposed	1 / 74 (1.35%)		
occurrences (all)	1		
Pain - Other			
subjects affected / exposed	7 / 74 (9.46%)		
occurrences (all)	9		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	3 / 74 (4.05%)		
occurrences (all)	7		
Diarrhea			
subjects affected / exposed	13 / 74 (17.57%)		
occurrences (all)	24		
Gastrointestinal - Other			
subjects affected / exposed	2 / 74 (2.70%)		
occurrences (all)	3		
Mucositis/stomatitis (clinical exam)			
subjects affected / exposed	3 / 74 (4.05%)		
occurrences (all)	7		
Mucositis/stomatitis (clinical exam) - Oral cavity			
subjects affected / exposed	5 / 74 (6.76%)		
occurrences (all)	14		
Nausea			
subjects affected / exposed	14 / 74 (18.92%)		
occurrences (all)	29		
Pain - Gastrointestinal - Abdomen NOS			
subjects affected / exposed	9 / 74 (12.16%)		
occurrences (all)	21		
Taste alteration (dysgeusia)			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 74 (2.70%)</p> <p>2</p> <p>4 / 74 (5.41%)</p> <p>6</p>		
<p>Hepatobiliary disorders</p> <p>AST, SGOT(serum glutamic oxaloacetic transaminase)</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>GGT (gamma-Glutamyl transpeptidase)</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 74 (1.35%)</p> <p>1</p> <p>1 / 74 (1.35%)</p> <p>2</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspnea (shortness of breath)</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hemorrhage, pulmonary/upper respiratory - Nose</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 74 (2.70%)</p> <p>3</p> <p>6 / 74 (8.11%)</p> <p>15</p> <p>6 / 74 (8.11%)</p> <p>28</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>Dermatology/Skin - Other</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hair loss/alopecia (scalp or body)</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Rash: hand-foot skin reaction</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 74 (8.11%)</p> <p>18</p> <p>7 / 74 (9.46%)</p> <p>25</p> <p>8 / 74 (10.81%)</p> <p>27</p>		
<p>Musculoskeletal and connective tissue disorders</p>			

Musculoskeletal/Soft Tissue - Other subjects affected / exposed occurrences (all)	2 / 74 (2.70%) 10		
Pain - Musculoskeletal - Back subjects affected / exposed occurrences (all)	1 / 74 (1.35%) 1		
Pain - Musculoskeletal - Bone subjects affected / exposed occurrences (all)	2 / 74 (2.70%) 8		
Pain - Musculoskeletal - Extremity- limb subjects affected / exposed occurrences (all)	1 / 74 (1.35%) 3		
Infections and infestations Infection - Other subjects affected / exposed occurrences (all)	2 / 74 (2.70%) 2		
Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 13		
Metabolic/Laboratory - Other subjects affected / exposed occurrences (all)	2 / 74 (2.70%) 3		
Weight loss subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 20		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 April 2010	Correction of several errors and further specification of technical details, mainly on samples for translational studies.
29 June 2012	Adjustment of the sample size to be recruited fornt-line into the study, as the proportion of patients qualifying for randomization after induction therapy was smaller than initially expected.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/26361971>

<http://www.ncbi.nlm.nih.gov/pubmed/30036739>

<http://www.ncbi.nlm.nih.gov/pubmed/27753609>